Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
marketed as Zadaxin in 35+ countries BPC-157 typical research dose / 200 to 500 mcg per day subcutaneous or oral, split or single injection Thymosin Alpha-1 typical research dose / 1.6 mg subcutaneous twice weekly (standard Zadaxin dosing) Primary BPC-157 mechanism / upregulates growth hormone receptor, promotes angiogenesis and collagen synthesis Primary Thymosin Alpha-1 mechanism / activates Toll-like receptor 9, drives Th1 CD4+ and CD8+ T-cell maturation Evidence quality for BPC-157 / animal models and case series
His research laid the groundwork for developing semaglutide and other GLP-1 drugs, which are sold under the brand names Ozempic, Rybelsus, Mounjaro and others
doi:10.1038/ijo.2013.162 19
TB-500 also promotes angiogenesis similar to BPC-157, reduces inflammation through cytokine modulation, and appears to have cardioprotective effects
Once again, GHK-Cu appeared to mediate its effects through decreased TNF-alpha and IL-6 expression [11]
